Eris Lifesciences (BOM:540596) Institutional Ownership: 23.62% (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540596 Eris Lifesciences Ltd BOM:540596
93 GF Score
Price ₹1,384.00
GF Value ₹1,659.93
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eris Lifesciences Institutional Ownership?

Eris Lifesciences BOM:540596 -0.39% 93 Institutional Ownership is 23.62% as of Aug. 09, 2026. GuruFocus rates BOM:540596 with a GF Score™ of 93/100 and a GF Value™ of ₹1,659.93 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Eris Lifesciences's institutional ownership is 23.62%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Eris Lifesciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Eris Lifesciences's Float Percentage Of Total Shares Outstanding is 0.00%.

Eris Lifesciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Eris Lifesciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eris Lifesciences Institutional Ownership Chart

Eris Lifesciences Historical Data

The historical data trend for Eris Lifesciences can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 23.23 23.49 23.59 23.68 23.72 23.37 23.51 23.62 23.59 23.62
BOM:540596
93GF Score
Eris Lifesciences Ltd BOM:540596
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eris Lifesciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 23.62% mean?
Eris Lifesciences (BOM:540596) has a Institutional Ownership of 23.62% as of Aug. 09, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Eris Lifesciences and its competitors.
Is Eris Lifesciences' Institutional Ownership too high?
Eris Lifesciences' current Institutional Ownership is 23.62%. Overall, Eris Lifesciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' Institutional Ownership compare to ZTS?
Eris Lifesciences' Institutional Ownership of 23.62% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Eris Lifesciences and its competitors. Eris Lifesciences's current Institutional Ownership is 23.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,659.93, compared to a current price of ₹1,384.00 — trading 16.6% below its estimated fair value. The current Institutional Ownership is 23.62%. Eris Lifesciences' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current Institutional Ownership is 23.62% as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eris Lifesciences (BOM:540596) Overvalued in 2026?

Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued. The current stock price of ₹1,384.00 is trading 16.6% below its estimated GF Value™ of ₹1,659.93. GuruFocus considers Eris Lifesciences to be Modestly Undervalued.

Key valuation signals for BOM:540596:

  • Institutional Ownership: 23.62%
  • GF Value™: ₹1,659.93 vs. price of ₹1,384.00 (16.6% below fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eris Lifesciences Business Description

Other Exchanges ERIS:India
Address Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
93GF Score

Get the complete analysis for BOM:540596

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,384.00
Price
₹1,659.93
GF Value